» Articles » PMID: 32169871

Pre-existing Inflammatory Immune Microenvironment Predicts the Clinical Response of Vulvar High-grade Squamous Intraepithelial Lesions to Therapeutic HPV16 Vaccination

Overview
Date 2020 Mar 15
PMID 32169871
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Vulvar high-grade squamous intraepithelial lesion (vHSIL) is predominantly induced by high-risk human papilloma virus type 16 (HPV16). In two independent trials, therapeutic vaccination against the HPV16 E6 and E7 oncoproteins resulted in objective partial and complete responses (PRs/CRs) in half of the patients with HPV16 vHSIL at 12-month follow-up. Here, the prevaccination and postvaccination vHSIL immune microenvironment in relation to the vaccine-induced clinical response was investigated.

Methods: Two novel seven-color multiplex immunofluorescence panels to identify T cells (CD3, CD8, Foxp3, Tim3, Tbet, PD-1, DAPI) and myeloid cells (CD14, CD33, CD68, CD163, CD11c, PD-L1, DAPI) were designed and fully optimized for formalin-fixed paraffin-embedded tissue. 29 prevaccination and 24 postvaccination biopsies of patients with vHSIL, and 27 healthy vulva excisions, were stained, scanned with the Vectra multispectral imaging system, and automatically phenotyped and counted using inForm advanced image analysis software.

Results: Healthy vulvar tissue is strongly infiltrated by CD4 and CD8 T cells expressing Tbet and/or PD-1 and CD14HLA-DR inflammatory myeloid cells. The presence of such a coordinated pre-existing proinflammatory microenvironment in HPV16 vHSIL is associated with CR after vaccination. In partial responders, a disconnection between T cell and CD14 myeloid cell infiltration was observed, whereas clinical non-responders displayed overall lower immune cell infiltration. Vaccination improved the coordination of local immunity, reflected by increased numbers of CD4Tbet T cells and HLA-DRCD14 expressing myeloid cells in patients with a PR or CR, but not in patients with no response. CD8 T cell infiltration was not increased after vaccination.

Conclusion: A prevaccination inflamed type 1 immune contexture is required for stronger vaccine-induced immune infiltration and is associated with better clinical response. Therapeutic vaccination did not overtly increase immune infiltration of cold lesions.

Citing Articles

GX-188E DNA vaccine plus pembrolizumab in HPV 16- and/or 18-positive recurrent or advance cervical cancer: a phase 2 trial.

Lim M, Choi Y, Hur S, Kim Y, No J, Kim B EClinicalMedicine. 2025; 74():102716.

PMID: 39823099 PMC: 11736335. DOI: 10.1016/j.eclinm.2024.102716.


Monocyte infiltration is an independent positive prognostic biomarker in vulvar squamous cell carcinoma.

Abdulrahman Z, Kortekaas K, Welters M, van Poelgeest M, van der Burg S Cancer Immunol Immunother. 2024; 73(9):166.

PMID: 38954042 PMC: 11219697. DOI: 10.1007/s00262-024-03755-w.


Bidirectional crosstalk between therapeutic cancer vaccines and the tumor microenvironment: Beyond tumor antigens.

Zhang S, Wang H, Ding X, Xiao Y, Shao Z, You C Fundam Res. 2024; 3(6):1005-1024.

PMID: 38933006 PMC: 11197801. DOI: 10.1016/j.fmre.2022.03.009.


A Vaccine against Cancer: Can There Be a Possible Strategy to Face the Challenge? Possible Targets and Paradoxical Effects.

Zefferino R, Conese M Vaccines (Basel). 2023; 11(11).

PMID: 38006033 PMC: 10674257. DOI: 10.3390/vaccines11111701.


CIMT 2023: report on the 20th Annual Meeting of the Association for Cancer Immunotherapy.

Dallmann J, Freitag J, Jung C, Khinvasara K, Merz L, Peters D Immunooncol Technol. 2023; 20:100397.

PMID: 37876518 PMC: 10590812. DOI: 10.1016/j.iotech.2023.100397.


References
1.
Welters M, Kenter G, Piersma S, Vloon A, Lowik M, Berends-van der Meer D . Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res. 2008; 14(1):178-87. DOI: 10.1158/1078-0432.CCR-07-1880. View

2.
Kenter G, Welters M, Valentijn A, Lowik M, Berends-van der Meer D, Vloon A . Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med. 2009; 361(19):1838-47. DOI: 10.1056/NEJMoa0810097. View

3.
Whiteside T, Demaria S, Rodriguez-Ruiz M, Zarour H, Melero I . Emerging Opportunities and Challenges in Cancer Immunotherapy. Clin Cancer Res. 2016; 22(8):1845-55. PMC: 4943317. DOI: 10.1158/1078-0432.CCR-16-0049. View

4.
Aulmann S, Schleibaum J, Penzel R, Schirmacher P, Gebauer G, Sinn H . Gains of chromosome region 3q26 in intraepithelial neoplasia and invasive squamous cell carcinoma of the vulva are frequent and independent of HPV status. J Clin Pathol. 2008; 61(9):1034-7. DOI: 10.1136/jcp.2008.056275. View

5.
Davoli T, Uno H, Wooten E, Elledge S . Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science. 2017; 355(6322). PMC: 5592794. DOI: 10.1126/science.aaf8399. View